

Seasonal Influenza Prevention in Older Adults

Addressing the Challenges

Satellite Symposium



Tuesday, September 12th, 2017






Introduction

Influenza infection causes significant morbidity and mortality in older adults ≥ 65 years of age. This burden in the 65+ age group, even within countries with commendable vaccination coverage, may be partly explained by the suboptimal clinical effectiveness of standard influenza vaccines in older people due to immunosenescence. There is currently an unmet clinical need in adults aged 65+ for an influenza vaccine that can offer enhanced protection.

Understanding the potential benefits of current age-specific influenza vaccines is important from a patient counseling perspective. This symposium will provide answers to commonly asked questions around recently introduced seasonal influenza vaccines for older adults in Europe, through a round table discussion with experts as well as addressing questions from participants.



Bios

MODERATOR

SUE SAVILLE

MA

Sue is a highly-experienced TV news journalist with a specialism in medical matters. She was Medical Correspondent at ITV News for many years and now freelances for national news, alongside chairing conferences and medical symposia, hosting awards events, running media and PR training, consulting to the pharmaceutical industry and making corporate films.

- Correspondent at ITV News for 15 years, mostly as Medical Correspondent
- Chief Correspondent at GMTV for 5 years (news service provided by Reuters)
- BBC Breakfast News Reporter
- BBC regional TV and Radio Reporter
- BBC Graduate News Trainee
- Hong Kong Commercial Radio presenter & Asia TV presenter
- Cardiff University Postgraduate Diploma in Journalism Studies
- MA History from Oxford University

SPEAKER

GEORGE KASSIANOS

MD (Hons), FRCGP, FBIHS, FESC, FBGTHA, FHEA, FAcadMEd, FFTM RCPS Glasg

Dr. George Kassianos is a General Practitioner based in England, UK. Dr. Kassianos studied medicine in Poland at the Medical Academy of Lodz. He trained as a General Practitioner at the London Hammersmith and St. Mary's Hospitals in London.

He is a member of the British Medical Journalists' Association and was Editor-in-Chief of the international journal *Drugs in Context* for 10 years (now the Associate Editor), past Medical Editor of the journals *Audit in General Practice*, *Care of the Elderly*, *Managing Heart Failure in General Practice*. Editorial Board member of journals *The British Journal of Cardiology*, *Geriatric Medicine*, *Primary Care Cardiovascular Journal*, *The British Journal of Family Medicine*, and is the GP editorial consultant for the journal *Guidelines in Practice*.

He is currently preparing the 5th edition of his book '*Immunisation Childhood and Travel Health*', member of the International Society of Travel Medicine, and President of the British Global & Travel Health Association (BGTHA). He has published research papers on the willingness of European healthcare workers to undergo Influenza vaccination, Pneumococcal Infection in Europe, Herpes Zoster, Atrial Fibrillation in Primary Care, and chair of the Guidelines Panel on Myalgia in Patients Who Are Taking Statins.

George Kassianos is the National Immunisation Lead and Cardiovascular Representative for the Royal College of General Practitioners, of which he is also a Fellow. He is also Fellow of the Faculty of Travel Medicine Royal College of Physicians & Surgeons of Glasgow, Higher Education Academy, Academy of Medical Educators, British & Irish Hypertension Society, the BGTHA, and the European Society of Cardiology. He chairs the Pan-European Committee on influenza RAISE (Raise Awareness of Influenza Strategies in Europe).

SPEAKER

PAUL VAN BUYNDER

MBBS, MPH, FAFPHM

Professor Van Buynder completed undergraduate medical training at Melbourne University and a postgraduate Public Health Masters degree at Sydney University.

He has worked in senior public health positions in a number of Australian states, in Canada and at the Centre for Infections in the United Kingdom.

He is currently a professor in the School of Medicine at Griffith University on the Gold Coast and the Chairman of the Australian Immunisation Coalition.

His research interests include, effectiveness and tolerability of enhanced influenza vaccines, the use of antivirals in long term care facilities and the marketing of vaccine programs to vaccine hesitant groups

SPEAKER

ADOLFO GARCÍA-SASTRE

PhD

Dr. García-Sastre is Professor in the Departments of Microbiology and Medicine and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York. For the past 25 years, his research interest has been focused on the molecular biology of influenza viruses and several other negative strand RNA viruses. During his post-doctoral training in the early 1990s, he developed, for the first time, novel strategies for expression of foreign antigens by a negative strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including 1) the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA, (studies in collaboration with Dr. Palese); 2) the generation and evaluation of negative strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and 3) the identification of the biological role of the non structural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system.

His research has resulted in more than 490 scientific publications and reviews. Dr. García-Sastre is the director of the Center for Research on Influenza Pathogenesis, one of the five NIAID funded Centers of Excellence for Influenza Research and Surveillance. He was among the first members of the Vaccine Study Section and member of the Virology B Study Section of NIH. In addition, he has served for 5 years as Editor in Journal of Experimental Medicine, is Editor in PLoS Pathogens, Journal of Virology and Virus Research, and member of the Editorial Board of Virology, Vaccine, NPJ Vaccines, Current Topics in Microbiology and Immunology and Influenza and Other Respiratory Diseases. He is a member of the scientific advisory board of Keystone Symposia. He has been a co-organizer of the international course on Viral Vectors (2001), held in Heidelberg, Germany, sponsored by Federation of European Biochemical Societies (FEBS), and of the first Research Conference on Orthomyxoviruses in 2001, held in Teixel, The Netherlands, sponsored by the European Scientific Working Group on Influenza (ESWI). He has also been a co-organizing of the 7th International Society for Vaccines meeting in 2013, and of Keystone Meetings in 2014 on Respiratory Virus Pathogenesis and in 2017 on Interferons. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 has been awarded with the distinction of the paper of the year 2005 by Lancet. In 2005, he became a Fellow of the American Academy of Microbiology, and in 2009, he received the Beijerinck Professorship from the National Academy of Sciences of the Netherlands. In 2011, he has been elected President of the International Society for Vaccines, for 2014 and 2015. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain.

SPEAKER

MARCO BARBIERI

BSc, MSc

Marco Barbieri holds a BSc in Economics from the University of Bologna and MSc in health economics from the University of York in 1999. He joined the team for economic evaluation of health technologies in 2000 as a Research Fellow and he spent two years working in a wide range of research including cost-effectiveness modelling in rheumatoid arthritis and cardiovascular disease, study of patient preference measurement and the application of evidence to decision making in health care. In the following years, he has worked as a Research Associate for the i3Innovus Research Ltd (now OptuminSight) and gained a position as a Associate Lecturer at the CRES (Economics and Health Research Centre), University Pompeu Fabra, Barcelona (Spain). He has been involved in several health technology assessments, both in the UK and in Italy, in areas such as mental disorders, cancer treatments and influenza vaccines, His particular field of interest is associated with issues of transferability of data among jurisdictions. He is a lecturer at the Summer School in Public Health Policy, Economics and Management, at the Università della Svizzera Italiana, Lugano, Switzerland and at the Executive Master in Healthcare and Pharmaceutical Administration, LUISS Business School, Rome, Italy. He is currently a Honorary Research Fellow at the Centre for Health Economics, University of York.



Seasonal Influenza Prevention in Older Adults

Addressing the Challenges



Notes:

Question for the panel:

Question for the panel:



Disclaimer: The information provided in this document is provided “as is” without warranty of any kind; either express or implied, and is intended for medical and scientific informational purposes only. The information contained herein is subject to change at any time without notice. All rights reserved. All trademarks mentioned herein belong to their respective owners.

US/GLB/FLUD/0817/0014